Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

738
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
738
Drug Therapy01:28

Drug Therapy

96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
96
Clinical Trials: Overview01:11

Clinical Trials: Overview

3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

842
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
842
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.7K
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomic markers enhance mortality prediction in heart failure.

European heart journal·2026
Same author

Evidence and opportunities for preeclampsia and cardiovascular disease prevention in malaria endemic settings.

Communications medicine·2026
Same author

Maternal Readiness for Newborn Self-Care in the Early Postpartum Period: Associations with Maternal Psychophysical State and Declared Breastfeeding Readiness.

Journal of clinical medicine·2026
Same author

Balancing policy ambition and systems reality in expanding access to NCD medicines: lessons from Ghana and Georgia.

Health policy and planning·2026
Same author

Obesity Definitions and Hospital Stay in Older Adults with Heart Failure: A Post Hoc Analysis of a Prospective Cohort.

Cardiac failure review·2026
Same authorSame journal

A Thematic Analysis of Key Informant Interviews on the Implementation Experience of the HEARTS Hypertension Program in Nigeria.

Global heart·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Global heart·2026
Same journal

Understanding Behavioural Determinants of Cardiovascular Disease and Stroke Prevention Among Culturally and Linguistically Diverse Communities: A Qualitative Descriptive Study.

Global heart·2026
Same journal

Co-Developing Strategies for Patient Engagement in Decentralized Rheumatic Heart Disease Care: Lessons from Northern Uganda.

Global heart·2026
Same journal

<i>Streptococcus Pyogenes</i> and Acute Rheumatic Fever: How Strong are the Links in the Chain?

Global heart·2026
Same journal

Joint Associations of Cumulative C-Reactive Protein-Triglyceride-Glucose Index and Depression with Cardiovascular Outcomes in Middle-Aged and Older Adults: A National Prospective Cohort Study.

Global heart·2026
See all related articles

Related Experiment Video

Updated: Sep 9, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.8K

WHF Roadmap on Single Pill Combination Therapies.

Enrico G Ferro1,2, Gautam Satheesh3,4,5, José Castellano6

  • 1Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States.

Global Heart
|September 2, 2025
PubMed
Summary
This summary is machine-generated.

Single pill combinations (SPCs) improve cardiovascular disease (CVD) treatment adherence and reduce risk. This roadmap addresses barriers and offers solutions for wider SPC implementation, especially in low-resource settings.

Keywords:
Cardiovascular diseasepolypillpreventionsingle pill combinations

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.0K

Related Experiment Videos

Last Updated: Sep 9, 2025

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.8K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.0K

Area of Science:

  • Cardiology
  • Public Health
  • Health Systems Research

Background:

  • Cardiovascular diseases (CVDs) are the primary global cause of death.
  • Poor treatment adherence is a significant obstacle in CVD prevention and management.
  • Single pill combinations (SPCs) offer a strategy to simplify medication regimens and enhance patient adherence.

Purpose of the Study:

  • To synthesize current clinical evidence on Single Pill Combinations (SPCs) for cardiovascular disease (CVD) management.
  • To identify key barriers hindering the widespread implementation and accessibility of SPCs globally.
  • To propose actionable, context-specific solutions for improving SPC integration into national health strategies.

Main Methods:

  • A comprehensive review of the latest clinical evidence regarding SPCs.
  • Analysis of global expert input and health systems to identify implementation challenges.
  • Development of a roadmap with practical strategies for SPC scale-up and accessibility.

Main Results:

  • SPCs effectively improve treatment adherence and reduce cardiovascular risk.
  • Key barriers include manufacturing limitations, cost, regulatory hurdles, and inconsistent clinical guidelines.
  • The roadmap provides tailored solutions for diverse healthcare settings, prioritizing low- and middle-income countries.

Conclusions:

  • Addressing identified barriers is crucial for maximizing the benefits of SPCs in CVD prevention.
  • Implementing the proposed solutions can enhance access to and effective utilization of SPCs.
  • This roadmap serves as a vital resource for stakeholders aiming to improve CVD care through evidence-based, patient-centered strategies.